Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
EXTON, Pa., Feb. 16, 2016 -- Fibrocell Science, Inc., (NASDAQ:FCSC), an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs, today announced that David Pernock, Chairman and Chief Executive Officer, will present at the RBC Capital Markets 2016 Global Healthcare Conference at 2:35 p.m. ET on Tuesday, February 23 in New York City.
A live audio webcast of Fibrocell’s presentation will be available under the News & Events section of the company’s website at http://ir.fibrocell.com/ and archived for 30 days. Please visit Fibrocell’s website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
Fibrocell Trademarks
Fibrocell™ and Fibrocell Science® are trademarks of Fibrocell Science, Inc. and/or its affiliates. All other names may be trademarks of their respective owners.
About Fibrocell
Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. Fibrocell’s most advanced product candidate, azficel-T, uses its proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of vocal fold scarring resulting in chronic or severe dysphonia. In collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is also developing gene therapies for skin and joint diseases using genetically-modified autologous fibroblasts. Fibrocell is in preclinical development of FCX-007, its orphan gene-therapy product candidate for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is also in preclinical development of FCX-013, its gene-therapy product candidate for the treatment of linear scleroderma. In addition, Fibrocell and Intrexon will be commencing preclinical development of a gene therapy for the treatment of chronic inflammatory and degenerative diseases of the joint, including arthritis and related conditions. For more information, visit www.fibrocell.com.
Investor Relations Contact: John Woolford Westwicke Partners 443.213.0506 [email protected] Media Relations Contact: Michael Parks 484.356.7105 [email protected]
